, Tracking Stock Market Picks
Enter Symbol:

up 23.15 %

MEDIVATION INC (MDVN) rated Buy with price target $88 by CRT Capital

Posted on: Tuesday,  Jan 28, 2014  8:25 AM ET by CRT Capital

CRT Capital rated Buy MEDIVATION INC (NASDAQ: MDVN) on 01/28/2014, when the stock price was $74.76. Since
then, MEDIVATION INC has gained 23.15% as of 01/27/2016's recent price of $92.07.
If you would have followed this CRT Capital's recommendation on MDVN, you would have gained 23.15% of your investment in 729 days.

Medivation, Inc. is a biopharmaceutical company with small molecule drugs in clinical development to treat three medical needs: Alzheimer?s disease, Huntington?s disease and castration-resistant prostate cancer. The Company has formed separate subsidiaries to hold the product candidates it is developing. The Company?s subsidiary Medivation Neurology, Inc. holds its Dimebon technology, and its subsidiary Medivation Prostate Therapeutics, Inc. holds its MDV300 series technology.

CRT Capital has consistently provided its clients with creative, idea-driven advice and solutions through targeted research and trading of High-Yield, Distressed, Convertible, and Emerging Market Debt Securities and Equities.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/28/2014 8:25 AM Buy
74.76 88.00
as of 10/17/2014
1 Week up  1.36 %
1 Month down  -3.76 %
3 Months up  35.48 %
1 YTD up  26.09 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy